Polarean Inc, based in Durham, NC, is a revenue-generating medical imaging technology company specializing in high-resolution imaging for pulmonary medicine. The company aims to revolutionize respiratory healthcare by leveraging MRI technology to evaluate lung function, diagnose diseases, monitor disease progression, and assess treatment responses.
With a focus on hyperpolarization science, Polarean has developed the first FDA-approved hyperpolarized MRI contrast agent, XENOVIEW xenon Xe 129, for visualizing and quantifying gas exchange in the lungs. Led by a team of experienced executives, including CEO Christopher von Jako and Founder/CTO Bastiaan Driehuys, Polarean is dedicated to addressing the global unmet medical needs of millions of patients with chronic respiratory diseases.
Generated from the website